Viking Therapeutics: A Biotech Balancing Act Between Promise and Financial Pressure

The competitive landscape for obesity treatments is heating up, fueling speculation about potential industry consolidation. At the center of this discussion is Viking Therapeutics, a clinical-stage biotech whose advanced drug candidate has made it a frequent subject of takeover rumors. However, the company’s story is one of contrasting narratives: significant clinical progress paired with mounting financial losses and no commercial revenue.

Viking’s primary asset, VK2735, is a dual GLP-1/GIP receptor agonist in late-stage development. This candidate is the cornerstone of the company’s value and the primary reason it is viewed as an attractive acquisition target, especially following the recent bidding war between Pfizer and Novo Nordisk for Read more...